Advances in radiotherapy and combination therapies for RET-positive refractory thyroid cancer
10.3760/cma.j.cn113030-20240926-00373
- VernacularTitle:RET阳性难治性甲状腺癌的放疗及联合治疗研究进展
- Author:
Jiaming LI
1
;
Fenfang FU
;
Benhua XU
;
Xiaobo LI
Author Information
1. 福建医科大学医学影像学院，福建医科大学附属协和医院放疗科，福建医科大学肿瘤中心，福建省肿瘤智能影像与精准放疗重点实验室，福建省消化、血液系统与乳腺恶性肿瘤放射与治疗临床医学研究中心，福州 350001
- Publication Type:Journal Article
- Keywords:
Radiotherapy, external beam;
RET gene;
Refractory thyroid cancer;
Tyrosine kinase inhibitor;
Combination therapy
- From:
Chinese Journal of Radiation Oncology
2025;34(11):1146-1152
- CountryChina
- Language:Chinese
-
Abstract:
Thyroid cancer is one of the most common malignancies of the endocrine system, and rearranged during transfection ( RET) gene alterations play a pivotal role in the incidence and progression of refractory thyroid cancer. In some patients, RET gene alterations lead to impaired iodine uptake or resistance to radioactive iodine, resulting in RET-positive radioactive iodine-refractory thyroid cancer. In recent years, radiotherapy has remained a cornerstone in the management of refractory thyroid cancer, while emerging therapeutic strategies, such as molecular targeted therapy—particularly with tyrosine kinase inhibitors—have overcome some of the limitations of conventional treatments and improved patient outcomes. However, given the limitations of monotherapy, developing combination approaches that integrate radiotherapy with other modalities has become increasingly important and represents a major clinical challenge. In this article, recent advances in the treatments of RET-positive refractory thyroid cancer were reviewed and the future prospects of combined therapeutic strategies for this disease were discussed.
